| Name | Title | Contact Details |
|---|
Umoja is developing a new approach to cancer therapy that retools a patient`s immune system in vivo, enhancing the body`s natural capacity to fight cancer. We envision a world where all patients with cancer have access to the most advanced immunotherapies and are free from the burdens of traditional cancer therapies.
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen, a first-in-class anti-cancer peptide-drug conjugate that rapidly delivers an alkylating payload into tumor cells. Melflufen is in development as a new treatment for the hematological cancer multiple myeloma and is currently being evaluated in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study. Oncopeptides` headquarters is in Stockholm, Sweden with U.S. headquarters in Boston, Mass. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.
ZEST Dental Solutions has been manufacturing overdenture implant attachment systems as a global leader and being one of the top dental implant manufacturers for over forty years.
CPL is a leading contract development and manufacturing organization (CDMO) that provides development, manufacturing, packaging, and testing of non-sterile liquid and semi-solid pharmaceutical and regulated OTC products.
Virdante Pharmaceuticals, Inc. is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.